Literature DB >> 15647719

Advances in diabetes for the millennium: chronic microvascular complications of diabetes.

Leann Olansky1.   

Abstract

Hyperglycemia and microvascular complications of retinopathy, nephropathy, and neuropathy are shared by type 1 and type 2 diabetes. These complications seem to be uniquely associated with the diabetic state in humans and animals; they are not seen in nondiabetic humans or animals. Intervention trials aimed at achieving lower blood glucose levels as reflected in a lower HbA1c value have shown reductions in the rate of development of those complications when HbA1c is lower in one group compared with a matched group with less good control. Currently, 3 schools of thought have been championed to explain elevated blood glucose. Each is discussed here, as are interventions aimed at the various metabolic derangements rather than at correction of the hyperglycemia.

Entities:  

Mesh:

Year:  2004        PMID: 15647719      PMCID: PMC1474833     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  13 in total

Review 1.  Advanced glycation end-products: a review.

Authors:  R Singh; A Barden; T Mori; L Beilin
Journal:  Diabetologia       Date:  2001-02       Impact factor: 10.122

2.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.

Authors:  P Gaede; P Vedel; H H Parving; O Pedersen
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

Review 3.  Protein kinase C activation and its pharmacological inhibition in vascular disease.

Authors:  M Meier; G L King
Journal:  Vasc Med       Date:  2000       Impact factor: 3.239

4.  Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE.

Authors:  C J He; T Koschinsky; C Buenting; H Vlassara
Journal:  Mol Med       Date:  2001-03       Impact factor: 6.354

Review 5.  Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications.

Authors:  E A Friedman
Journal:  Diabetes Care       Date:  1999-03       Impact factor: 19.112

6.  The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data.

Authors:  A Nicolucci; F Carinci; J G Graepel; T C Hohman; F Ferris; J M Lachin
Journal:  Diabetes Care       Date:  1996-10       Impact factor: 19.112

7.  Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients.

Authors:  K Kiuchi; J Nejima; T Takano; M Ohta; H Hashimoto
Journal:  Heart       Date:  2001-01       Impact factor: 5.994

8.  Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin.

Authors:  T S Kern; R L Engerman
Journal:  Diabetes       Date:  2001-07       Impact factor: 9.461

9.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

Review 10.  The cellular and molecular mechanisms of diabetic complications.

Authors:  G L King; M Brownlee
Journal:  Endocrinol Metab Clin North Am       Date:  1996-06       Impact factor: 4.741

View more
  2 in total

1.  Prevalence and risk factors for myopia in Taiwanese diabetes mellitus patients: a multicenter case-control study in Taiwan.

Authors:  Hsin-Ting Lin; Cai-Mei Zheng; Yu-Ann Fang; Ju-Chi Liu; Yun-Chun Wu; Yun-Hsiang Chang; Jiann-Torng Chen; Chang-Min Liang; Tian-Jong Chang; Jing-Quan Zheng; Ming-Cheng Tai; Yuh-Feng Lin
Journal:  Sci Rep       Date:  2021-04-14       Impact factor: 4.379

2.  Short-term stability in refractive status despite large fluctuations in glucose levels in diabetes mellitus type 1 and 2.

Authors:  Byki Huntjens; W Neil Charman; Helena Workman; Sarah L Hosking; Clare O'Donnell
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.